Simulations Plus (NASDAQ:SLP) Upgraded at StockNews.com

StockNews.com upgraded shares of Simulations Plus (NASDAQ:SLP) from a sell rating to a hold rating in a research report sent to investors on Friday.

SLP has been the subject of several other reports. KeyCorp raised their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $49.40.

Simulations Plus Stock Performance

NASDAQ SLP opened at $25.68 on Friday. Simulations Plus has a 1 year low of $23.01 and a 1 year high of $51.22. The business’s fifty day moving average is $30.03 and its two-hundred day moving average is $30.27. The stock has a market capitalization of $515.96 million, a P/E ratio of 64.20 and a beta of 1.13.

Simulations Plus (NASDAQ:SLP) last announced its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company had revenue of $22.43 million for the quarter, compared to analyst estimates of $21.93 million. During the same period in the previous year, the firm earned $0.20 earnings per share. Simulations Plus’s revenue for the quarter was up 22.5% compared to the same quarter last year. On average, research analysts forecast that Simulations Plus will post 1.09 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the sale, the director now owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. This trade represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 19.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Conestoga Capital Advisors LLC lifted its holdings in shares of Simulations Plus by 15.0% during the 4th quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company’s stock valued at $62,090,000 after buying an additional 290,414 shares during the last quarter. State Street Corp lifted its stake in Simulations Plus by 4.7% in the third quarter. State Street Corp now owns 640,303 shares of the technology company’s stock valued at $20,503,000 after acquiring an additional 28,953 shares during the last quarter. Ameriprise Financial Inc. grew its position in Simulations Plus by 16.7% in the fourth quarter. Ameriprise Financial Inc. now owns 607,902 shares of the technology company’s stock worth $16,954,000 after acquiring an additional 86,868 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Simulations Plus by 7,753.3% during the 4th quarter. Janus Henderson Group PLC now owns 542,899 shares of the technology company’s stock worth $15,141,000 after purchasing an additional 535,986 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Simulations Plus by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock valued at $14,367,000 after purchasing an additional 18,924 shares in the last quarter. 78.08% of the stock is owned by institutional investors and hedge funds.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.